Oncology-focused drug development company that identifies differentiated therapeutic assets originating in Asia, then in-licenses or acquires them and advances them through clinical development in the US and other global markets
Oncology-focused drug development company that identifies differentiated therapeutic assets originating in Asia, then in-licenses or acquires them and advances them through clinical development in the US and other global markets. Its team emphasizes translational science, clinical execution, regulatory and commercial positioning, and development toward globally competitive medicines.
The top three firms on F4's Biotech & Life Sciences investor list.